Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the Philadelphia chromosome and BCR::ABL1 oncoprotein.
• Tyrosine kinase inhibitors (TKIs) revolutionized CML treatment starting in 2001.
• Acquired resistance to TKIs, often due to mutations like T315I, remains a significant clinical challenge.

Purpose of the Study:

• To review current knowledge on the T315I mutation in CML.
• To explore optimal treatment strategies for T315I-mutated CML.
• To discuss the role of third-generation TKIs and future therapeutic directions.

Main Methods:

• Narrative review of existing literature.
• Analysis of clinical data regarding T315I mutations.
• Examination of therapeutic options and emerging strategies.

Main Results:

• The T315I mutation confers resistance to many approved TKIs.
• Third-generation TKIs show promise in overcoming T315I-mediated resistance.
• Identifying effective therapies for T315I-mutated CML is critical for improving patient prognosis.

Conclusions:

• The T315I mutation presents a major hurdle in CML management.
• Targeted therapies, particularly newer generation TKIs, are essential for resistant CML.
• Ongoing research into novel therapeutic strategies is vital for advancing CML treatment.